Comparing GLIADEL Chemotherapy Wafers to Stereotactic Radiosurgery After Brain Tumor Surgery in Adults with Metastatic Brain Cancer

What this Trial Is About

Researchers are evaluating whether placing GLIADEL wafers, a local chemotherapy, directly into the site where a metastatic brain tumor was surgically removed can prevent the tumor from coming back as well as stereotactic radiosurgery SRS given after surgery. This trial is for adults with one to four metastatic brain tumors, focusing on comparing GLIADEL to SRS after tumor removal to see which better prevents local recurrence. Participants with certain types of cancers or prior brain radiation are not eligible, and they should have a life expectancy greater than three months. Participants will be randomly assigned during surgery to either receive GLIADEL wafers placed in the resection cavity immediately after tumor removal or to receive SRS to the cavity within six weeks after surgery. Any other tumors will be treated with SRS. The amount of GLIADEL wafers used depends on the cavity size to cover as much area as possible. Before surgery, participants will have brain MRI scans and cognitive testing. After surgery, another MRI will check how much tumor was removed. Participants will be monitored regularly to check for tumor recurrence and changes in cognitive function. Researchers will also analyze the genetic makeup of the brain tumor compared to the primary cancer and normal cells. The main outcome measured is how effective GLIADEL is compared to SRS over 12 months.

A Study Comparing GLIADEL to Stereotactic Radiosurgery in Metastatic Brain Disease